333 related articles for article (PubMed ID: 38067366)
1. Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies.
Chen C; Jung A; Yang A; Monroy I; Zhang Z; Chaurasiya S; Deshpande S; Priceman S; Fong Y; Park AK; Woo Y
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067366
[TBL] [Abstract][Full Text] [Related]
2. A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept.
Mahasa KJ; Ouifki R; Eladdadi A; Pillis L
Math Biosci Eng; 2022 Mar; 19(5):4429-4457. PubMed ID: 35430822
[TBL] [Abstract][Full Text] [Related]
3. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
4. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.
Mardi A; Shirokova AV; Mohammed RN; Keshavarz A; Zekiy AO; Thangavelu L; Mohamad TAM; Marofi F; Shomali N; Zamani A; Akbari M
Cancer Cell Int; 2022 Apr; 22(1):168. PubMed ID: 35488303
[TBL] [Abstract][Full Text] [Related]
5. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.
Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H
World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068
[TBL] [Abstract][Full Text] [Related]
6. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
McGrath K; Dotti G
Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
[TBL] [Abstract][Full Text] [Related]
7. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
10. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
Qian S; Villarejo-Campos P; García-Olmo D
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768570
[TBL] [Abstract][Full Text] [Related]
11. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma.
Fang L; Tian W; Zhang C; Wang X; Li W; Zhang Q; Zhang Y; Zheng J
Pharmacol Res; 2023 Mar; 189():106701. PubMed ID: 36796464
[TBL] [Abstract][Full Text] [Related]
13. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
14. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
[TBL] [Abstract][Full Text] [Related]
15. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.
Jung M; Yang Y; McCloskey JE; Zaman M; Vedvyas Y; Zhang X; Stefanova D; Gray KD; Min IM; Zarnegar R; Choi YY; Cheong JH; Noh SH; Rha SY; Chung HC; Jin MM
Mol Ther Oncolytics; 2020 Sep; 18():587-601. PubMed ID: 32995483
[TBL] [Abstract][Full Text] [Related]
17. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
[TBL] [Abstract][Full Text] [Related]
20. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]